Explore original, structured summaries for research and education.
Research profile
GHK-Cu
GHK-Cu is indexed as a Copper tripeptide research entry. Its current evidence category is Well Studied, and published discussion commonly places it within Healing & Recovery, Longevity, Skin & Hair. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- 404.96 Da
- Chain length
- 3 amino acids
- Type
- Copper tripeptide
- Reported half-life
- 0.5-2 hours
Gly-His-LysLiterature map
Research indications
Skin Regeneration
- Collagen Synthesismost effective
- Elastin Productionmost effective
- Skin Barrier Functioneffective
Hair Growth
- Follicle Stimulationeffective
- Scalp Healtheffective
Anti-Inflammatory
- Immune Modulationmoderate
- Tissue Protectionmoderate
Evidence-gated guidance
Dosing Protocols
No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for GHK-Cu. Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of GHK-Cu cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is GHK-Cu approved for personal use?
This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene DataPickart, L., Margolina, A. · International Journal of Molecular Sciences · 2018
- GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin RegenerationPickart, L., Vasquez-Soltero, J.M., Margolina, A. · BioMed Research International · 2015
- The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive healthPickart, L., Vasquez-Soltero, J.M., Margolina, A. · Oxidative Medicine and Cellular Longevity · 2012
- Tripeptides GHK and GHK-Cu-modified silver nanoparticles for enhanced antibacterial and wound healing activitiesIslam, R., Bilal, H., Wang, X., Zhang, L. · Colloids and Surfaces B: Biointerfaces · 2024
- Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospectiveMortazavi, S.M., Mohammadi Vadoud, S.A., Moghimi, H.R. · BioImpacts · 2024
